Targeting the Programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) immune checkpoint pathway has emerged as a promising strategy for NKTCL treatment, and several studies have been conducted to evaluate its prognostic significance as well. This evidence concerns the gene PDCD1 and extranodal nasal NK/T cell lymphoma.